VX-708

VX-708 is a small molecule drug developed by Vertex Pharmaceuticals. It acts as an inhibitor of voltage-gated sodium channels (VGSCs), functioning as a blocker to reduce neuronal excitability. The primary therapeutic area under investigation is acute pain, with the drug being evaluated for its analgesic properties in Phase 1 clinical trials. As of June 2025, there are no approved indications for VX-708, and it remains in early-stage clinical development[2][5]. The mechanism of action involves blocking voltage-gated sodium channels, which play a key role in the initiation and propagation of action potentials in neurons[2][5].